MARKSANS PHARMA LTD. - 524404 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
In compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, herewith a copy of the Certificate received from Bigshare Services Private Limited., the Registrar and Share Transfer Agent of our Company is enclosed herewith, for the quarter ended September 30, 2019. Marksans Pharma Ltd - 524404 - Regulation 40 (9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
We enclose herewith Certificate issued by S. S. Rauthan & Associates, Company Secretaries for the half year ended 30th September, 2019 as required under Regulation 40(9) & 40 (10) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Marksans Pharma Ltd - 524404 - Compliance Certificate - Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
As per the requirement of Regulation 7 (3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby confirm that activities in relation to both physical and electronic share transfer facility are maintained during the period April 1, 2019 to September 30, 2019 (both days inclusive) by the Company''s Registrar and Share Transfer Agent, viz., M/s. Bigshare Services Pvt. Ltd. Marksans Pharma Ltd - 524404 - Statement Of Investor Complaints For The Quarter Ended September 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Harshavardhan PanigrahiDesignation :- Company Secretary and Compliance Officer Marksans Pharma Ltd - 524404 - Minutes Of 27Th Annual General Meeting
We are pleased to enclose herewith copy of the Minutes of the proceedings of the 27th Annual General Meeting held on 26th September, 2019. MARKSANS PHARMA LTD. - 524404 - Closure of Trading Window
In terms of the Company's Code of Conduct to Regulate, Monitor and Report Trading by designated persons framed pursuant to SEBI (Prohibition of Insider Trading)(Amendment) Regulations, 2018, the trading window for dealing in the securities of Marksans Pharma Limited (the Company) for the insiders of the Company will remain closed with effect from Tuesday, 1st October, 2019 till 48 hours after the declaration of financial results for the quarter ended 30th September, 2019. The date of declaration of financial results will be intimated separately in due course of time. Marksans Pharma Ltd - 524404 - Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Marksans Pharma Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here Marksans Pharma Ltd - 524404 - Details Of Voting Results Of The 27Th Annual General Meeting Of Marksans Pharma Limited.
Details of voting results of the 27th Annual General Meeting of Marksans Pharma Limited held on Thursday, 26th September, 2019 at 10:30 AM at GMS Banquet, Opp. Indian Oil Nagar, D.N. Nagar Metro Station, New Link Road, Andheri (West), Mumbai - 400 053, along with Scrutinizers Report . MARKSANS PHARMA LTD. - 524404 - Shareholder Meeting / Postal Ballot-Outcome of AGM
The shareholders of the Company have, at the 27th Annual General Meeting held on 26th September, 2019: 1. Adopted the Standalone and Consolidated Audited Financial Statements of the Company for the financial year ended 31st March, 2019 together with the reports of the Board of Directors' and the Auditors' thereon. 2. Declared dividend of Rs. 0.05 (i.e. 5%) on Equity Shares of Re. 1/- each face value and dividend of Rs. 7.00 (i.e. 7%) on Redeemable Cumulative Preference Shares of Rs. 100/- each face value. The dividend will be paid on or after 4rd October, 2019. 3. Approved re-appointment of Mrs. Sandra Saldanha (DIN: 00021023), who retired by rotation and being eligible, offered herself for re-appointment. 4. Approved appointment of Mr. Abhinna Sundar Mohanty (DIN: 00007995) as an Independent Director of the Company for a period of five (5) consecutive years with effect from 11th July, 2019. 5. Approved Marksans Employees Stock Option Scheme 2019. MARKSANS PHARMA LTD. - 524404 - Proceedings Of The 27Th Annual General Meeting Of Marksans Pharma Limited Held On Thursday, September 26, 2019.
This is to inform you that the 27th Annual General Meeting ('AGM') of Marksans Pharma Limited ('the Company') was held on Thursday, September 26, 2019 and the business mentioned in the Notice dated August 9, 2019 was transacted.